The Influenza A Virus, H7N9 Subtype Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Influenza A Virus, H7N9 Subtype Infections. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued products.

GlobalData tracks 23 drugs in development for Influenza A Virus, H7N9 Subtype Infections by 21 companies/universities/institutes. The top development phase for Influenza A Virus, H7N9 Subtype Infections is preclinical with 11 drugs in that stage. The Influenza A Virus, H7N9 Subtype Infections pipeline has 15 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Influenza A Virus, H7N9 Subtype Infections pipeline products market are: Butantan Institute, German Center for Infection Research and New Amsterdam Sciences.

The key targets in the Influenza A Virus, H7N9 Subtype Infections pipeline products market include Hemagglutinin (H7HA), Neuraminidase A (nanA or EC 3.2.1.18), and RNA Polymerase (EC 2.7.7.6).

The key mechanisms of action in the Influenza A Virus, H7N9 Subtype Infections pipeline product include RNA Polymerase (EC 2.7.7.6) Inhibitor with one drug in Preclinical. The Influenza A Virus, H7N9 Subtype Infections pipeline products include seven routes of administration with the top ROA being Intramuscular and 11 key molecule types in the Influenza A Virus, H7N9 Subtype Infections pipeline products market including Small Molecule, and Inactivated Vaccine.

Influenza A Virus, H7N9 Subtype Infections overview

Avian influenza A (H7N9) is a subtype of influenza viruses known as “bird flu”. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia, and general malaise. Treatment includes antiviral drugs.

For a complete picture of Influenza A Virus, H7N9 Subtype Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.